MAIA BIOTECHNOLOGY Aktie

MAIA Biotechnology has activated the first US clinical site for the Phase‑2 expansion study THIO‑101 at Summit Medical Group in Jersey. The study is evaluating ateganosin as a third‑line therapy in advanced non‑small‑cell lung cancer in two arms (combination with cemiplimab and monotherapy); the US portion is funded with USD 2.3 million by the National Institutes of Health. MAIA plans four additional US sites in 2026, holds FDA Fast Track status for ateganosin, and reports a market capitalization of USD 86.15 million and a current ratio of 1.66. » More on de.investing.com

MAIA Biotechnologie placed 20 million shares at $1.50 each in a public capital raise of $30 million, representing a 27.5% discount to the closing price. The placement was led by healthcare investors and existing shareholders, with Konik Capital Partners as sole bookrunner. Proceeds will fund clinical trials, working capital and general corporate purposes; the stock fell 29% in premarket trading to $1.47. » More on de.investing.com

At the SITC 2025 conference, Maia Biotechnology presented two posters on ongoing clinical trials of Ateganosin (THIO) combined with immune checkpoint inhibitors in patients with advanced, previously treatment‑resistant non‑small cell lung cancer. The posters describe a phase‑3 study (THIO‑104) and a phase‑2 study (THIO‑101) and are available on the company website. Maia notes that the content includes forward‑looking statements and investors should not place undue weight on them. » More on de.investing.com